Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00369707 · ClinicalTrials.gov registry record · Phase 2
Trial of VELCADE and Rituxan as Front-line Tx for Low-grade NHL
A Phase 2 study, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT00369707 is a Phase 2 study that has completed, run by Northwestern University. The registered enrollment target is 42 participants.
The verdict
NCT00369707, a Phase 2 study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving bortezomib together with rituximab may kill more cancer cells. This phase II trial is studying how well giving bortezomib together with rituximab works as first-line therapy in treating patients with low-grade B-cell non-Hodgkin's lymphoma.
Interventions
- DRUG Rituximab
- DRUG bortezomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2006-08-09 |
| Est. Completion | 2014-10-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00369707
The ClinicalTrials.gov registry entry for NCT00369707 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rituximab is the first listed.
NCT00369707 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00369707 about?
NCT00369707 is a clinical study titled "Trial of VELCADE and Rituxan as Front-line Tx for Low-grade NHL". Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find ...
What is the current status of trial NCT00369707?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2006-08-09. Estimated completion is 2014-10-10.
What interventions are being tested in trial NCT00369707?
The interventions under investigation include: Rituximab (DRUG), bortezomib (DRUG).
Who is sponsoring clinical trial NCT00369707?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.